Serum insulin‐like growth factor‐1 is not a useful marker of prostate cancer

Abstract

Objective To determine whether the use of serum insubetween these groups. The PSA level and age of the patients diCered significantly between the groups (both lin-like growth factor 1 (IGF-1) levels is more eBcient than serum prostate specific antigen (PSA) levels in P<0.001). There was no correlation between IGF-1 and PSA levels, and even when the age diCerence in predicting prostate cancer in patients undergoing prostatic biopsy.the groups was considered, there was still no significant relationship between IGF-1 levels and the inciPatients and methods The study included 94 consecutive patients who required transrectal ultrasonography dence of prostate cancer. In patients with a PSA level of 4-20 mg/L there was no statistically significant (TRUS)-guided biopsies of their prostate and who had blood samples taken before their biopsies. These diCerence in IGF-1 levels between the groups. Conclusion Serum IGF-1 as a tumour marker does not samples were then analysed for IGF-1 and PSA concentrations. Six prostatic biopsies were taken from each help to predict patients with prostate cancer. PSA level and even age were better predictors of the presence of patient; they were assessed and a diagnosis made of prostate cancer or no malignancy.prostate cancer than were serum IGF-1 levels.

Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers

“…Chan et al (32) reported an association between serum IGF-I levels and the risk of prostate cancer. However, in other studies, a direct correlation between prostate cancer and serum IGF-I could not be found (33,34). IGF-II also plays a critical role in the autocrine and paracrine stimulation of prostatic neoplasms.…”

“…There is a lack of consensus regarding the influence of IGF-I on the etiology of prostate cancer (29)(30)(31)(32)(33)(34). Chan et al (32) reported an association between serum IGF-I levels and the risk of prostate cancer.…”

Study of Dj-1 protein in tissue specimens, cultured cells and serum of prostate cancer patients

“…Уже более десяти лет ведутся активные исследования, направленные на установление ассоциации риска РПЖ с уровнем белков IGF1 и IGFBP3, относящихся к системе инсулино-подобных факторов роста и участвующих в реализации пролиферативных и подавляющих апоптоз каскадных путей [18,20,21]. В нашей выборке средний сывороточный уровень IGF1 у больных РПЖ составил 97,35 нг/мл, тогда как у больных ДГПЖ -90,05 нг/мл.…”

IGF1 (CA)19 Repeat and IGFBP3 -202 A/C Genotypes and the Risk of Prostate Cancer in Black and White Men

“…However, a growing body of evidence suggests that serum insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) levels may play a role in prostate cancer risk and/or severity (5,6). Previous findings relating circulating levels of IGF-1 and IGFBP-3 to prostate cancer risk and severity have been intriguing, although not entirely consistent (5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24). Of note, a positive association between increased IGF-1 levels and prostate cancer was found in three prospective studies (12)(13)(14).…”